Ardelyx, Inc. (NASDAQ:ARDX) Q1 2023 Results Earnings Conference Call May 4, 2023 4:30 PM ET
Company Participants
Caitlin Lowie - Vice President, Corporate Communications and Investor Relations
Mike Raab - President and Chief Executive Officer
Susan Rodriguez - Chief Commercial Officer
Justin Renz - Chief Financial and Operations Officer
Conference Call Participants
Yigal Nochomovitz - Citi Research
Laura Chico - Wedbush Securities
Joseph Thome - TD Cowen
Christopher Raymond - Piper Sandler & Co.
Matthew Kaplan - Ladenburg Thalmann
Operator
Good day. And welcome to the Ardelyx First Quarter 2023 Conference Call. All participants will be in listen-only mode. [Operator Instructions]. Please note this event is being recorded.
I would now like to turn the conference over to Caitlin Lowie, Vice President of Corporate Communications and Investor Relations. Please go ahead.
Caitlin Lowie
Thank you. Good afternoon, everyone, and welcome to our first quarter financial results call. During this call, we will refer to the press release issued earlier today, which is available on the Investors section of the company's website at ardelyx.com.
During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors in our most recent quarterly report on Form 10-Q filed today, which can also be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
Our President and CEO, Mike Raab, will begin today's call with opening remarks and an overview of the company's progress during the first quarter of 2023. Next, Susan Rodriguez, Chief Commercial Officer, will provide an update on the launch of IBSRELA.
Justin Renz, Chief Financial and Operations Officer, will conclude today's formal remarks with a review of the company's financial performance during the first quarter ended March 31st, 2023 before we open the call to questions.
With that, let me pass the call over to Mike.
Mike Raab
Thank you, Caitlin. And good afternoon, everyone. I'm excited to be here today to highlight the momentum we've created at Ardelyx as we report another quarter of consistent growth for IBSRELA and the progress we've made on our path to bring XPHOZAH to patients.
In this afternoon's press release, we also announced a recent business development transaction designed to bring our novel mechanism products to patients and strengthen our cash position.